Maternal Malaria During Pregnancy - Baby Not Yet Delivered
Conditions
Brief summary
The overarching aims of this study are to longitudinally determine the occurrence of pregnancy in a cohort of nulligravida at the community level and to estimate the burden of malaria infection during the course of the pregnancy till delivery.
Detailed description
Three subgroups will involve in the design of this study: for subgroup 1, fieldworkers will visit the households in the study area to identify and enroll women meeting the eligibility criteria to involve in a nulligravida cohort aged ≥ 15 years. After consenting a fingerprick blood sample will be obtained for pregnancy testing, malaria blood smear, and VAR2CSA antibodies measurement. Enrolled women will be visited every trimester to check for pregnancy and malaria infection. The follow up of each participant will end upon a pregnancy test is positive or at month 9 after the enrolment. Participants to subgroup 2 will be enrolled primigravidae aged ≥ 15 years by study staff stationed at the antenatal care clinic. Women attending the ANC visit at any gestational age will be screened and those meeting the eligibility criteria will undergo the study procedures which includes collecting demographic data, medical and pregnancy history. They will then be requested to donate a fingerprick blood sample for malaria infection and hemoglobin measurement. This will be a single timepoint evaluation. Subgroup 3 participants will be recruited primigravidae aged ≥ 15 years during any of the ANC visit as consenting process will not be feasible during the labour at delivery. They will be issued a sticker that will be affixed to the health card so that they could easily be recognized when they come for delivery. At delivery, samples will be collected from fingerprick, cord blood and placenta for detecting malaria infection by microscopy and histopathology. Additional data will be collected on the neonate for secondary outcomes assessment.
Interventions
None listed
Sponsors
European Vaccine Initiative
Groupe de Recherche Action en Sante
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
15 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* For subgroup 1 * Nulligravidae aged ≥ 15 years * Residing within the study area and planning to stay for the study duration * Signed or thumb-printed informed consent obtained from participant/participant legally acceptable representatives. An assent will be obtained from minors. * For subgroups 2 and 3 * Primigravidae aged ≥ 15 years at the time of enrolment * Residing within the study area for the last three months * Signed or thumb-printed informed consent obtained from participant/participant legally acceptable representatives. An assent will be obtained from minors. * Additional criteria for subgroup 3 • Third trimester of gestational age
Exclusion criteria
* For subgroup 1 only * Women of non-childbearing potential. Non-childbearing potential is defined as current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. * Women reporting established use of oral, injected or implanted hormonal contraceptives; intrauterine device or intrauterine system * For all the subgroups * Chronic use of i) immunosuppressive drugs, ii) or other immune modifying drugs within three months prior to enrolment in the study * Known history of Human Immunodeficiency Virus (HIV) (No test will be done by the study) * Use of any other investigational or non-registered product (drug or vaccine) during the study period. * Any previous participation in any malaria (vaccine) study. * Any other condition or situation that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Placental infection | 9 months | Proportion of women at delivery with histopathologically confirmed placental infection |
| Proportion of nulliparous with positive urine test | 9 months | Proportion of nulliparous with positive urine pregnancy test at 3 months, 6 months and 9 months post enrolment |
| P. falciparum infection in nulliparous attending the antenatal care visit | 9 months | Prevalence of P. falciparum infection by microscopy and PCR (polymerase chain reaction) in nulliparous attending the antenatal care visit at the local health care facility |
| Moderate and severe anemia during the last antenatal care visit | 9 months | Proportion of pregnant women with moderate and severe anemia during the last antenatal care visit at the local health care facility |
| P. falciparum infection at delivery | 9 months | Prevalence of parasitemia at delivery (maternal and cord blood) by microscopy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse birth outcomes | 9 months | Prevalence of adverse birth outcomes (spontaneous abortion, stillbirth, low birth weight (\<2,500 g), preterm delivery (\<37 weeks)) |
| Uptake IPTp-SP (Intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine) during the pregnancy | 9 months | Proportion of pregnant women receiving one, two, three and ≥ 3 doses of IPT-SP during the pregnancy |
Other
| Measure | Time frame | Description |
|---|---|---|
| Titers of VAR2CSA (a large 350-kDa protein comprising six Duffy-binding-like (DBL) domains and three larger interdomain regions) antibodies in nulliparous | 3 months | Geometric mean titers of VAR2CSA antibodies at enrolment of nulliparous |
| Gametocytes presence in placental tissue | 9 months | Gametocytes prevalence in placental tissue |
| Prevalence of mutations among pregnancy | 9 months | Prevalence of dhps K540E, dhps A581G and dhfr I164L mutations (Markers of sulfadoxine-pyrimethamine resistance) |
Countries
Burkina Faso
Contacts
Primary ContactAlphonse OUEDRAOGO, MD, PhD
Backup ContactSodiomon B SIRIMA, MD, PhD, Pr
Outcome results
None listed